The major reorganization unveiled by Novartis CEO Vas Narasimhan on 4 April, which merges its standalone oncology unit with its pharma division and puts new emphasis on US commercial success, represents an admission that the company has been underperforming compared with its peers. (Also see "Novartis Restructure Sees Drug Development And Oncology Chiefs Exit" - Scrip, 4 April, 2022.)
Narasimhan said the changes were the logical next step in the progression from Novartis’s former conglomerate strategy towards a pure-play pharma company, but the reshuffle also aims to fix two fundamental problems: its disappointing performance in the all-important US
